$CTXR Lost in all the excitement over the E7777 acquisition, they still expect to publish the topline data for their ARDS sheep study by the end of this quarter (Sept 30). Preclinical topline isn't as huge as their Q4 catalysts, but you never know how the market will react to positive ARDS data. Especially in light of Delta being talked about on a daily basis.
1
26
26 Likes